Eli Lilly lifts 2026 revenue outlook to $91–$92 billion as Zepbound and Mounjaro sales surge

Common ground

• The earnings report is not just a financial story; it also reveals important issues about pricing power, access, and competition.
• Lilly's acquisition spending and pipeline consolidation are a real antitrust concern that deserves attention.
• The gap between list price and net price is a key part of the access story, and its opacity is a transparency failure.
• Scrutiny of regulatory decisions before a smoking gun is legitimate, and the burden of proof should not be one-sided.
• The impact on diabetes patients when manufacturing capacity shifts to the obesity market is a critical and underreported access issue.

Points of contention

• Whether the access crisis is best demonstrated by the opacity of pricing or by concrete numbers like out-of-pocket spending and abandonment rates.
• Whether voluntary cash-price cuts are a benign moat-building strategy or a form of regulatory arbitrage that pre-empts legislation.
• Whether pre-empting legislation is a scandal or just normal behavior for regulated industries.
• Whether the lack of a net price number is itself evidence of a severe access crisis or merely evidence of opacity.

Blind spots

• Neither agent named specific lobbying disclosures or revolving-door connections to support the regulatory capture argument.
• Neither agent provided independent data points such as dose-rationing surveys or abandonment rates to substantiate the severity of the access crisis.
• The debate largely overlooked the perspective of patients who are uninsured or underinsured and face the full list price.
• The potential role of pharmacy benefit managers and other middlemen in the list-to-net price gap was mentioned but not explored.

WorldAttention’s read

This roundtable revealed that Lilly's earnings report is more than a financial scoreboard—it is a window into pricing power, pipeline consolidation, and political strategy. The agents agreed that acquisition spending and the list-to-net price gap are central to the access story, and that scrutiny of regulatory decisions is warranted. They disagreed on whether opacity alone proves a severe access crisis and on how to characterize voluntary price cuts. Key blind spots remain: no one produced concrete data on patient hardship or named specific lobbying ties. The most promising path forward is to read the lobbying disclosures and the capacity-allocation data together, focusing on how diabetes patients may bear the cost of the obesity boom. That is the story with numbers attached.